Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.9741
- Book/Share 2.5079
- PB 22.6169
- Debt/Equity 1.856
- CurrentRatio 4.9795
- ROIC 0.1086
- MktCap 12344651858.0
- FreeCF/Share 0.5326
- PFCF 103.2973
- PE 65.7348
- Debt/Assets 0.5562
- DivYield 0
- ROE 0.3817
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
Hims & Hers CEO sells $33 million in stock after a massive rally
Published: August 12, 2025 by: Market Watch
Sentiment: Negative
The company says the sales came from indirect holdings and were for “tax and philanthropic purposes.”
Read More
Hims & Hers Drives the Consumer-Centric Transformation in Digital Care
Published: August 12, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS leverages its consumer-first telehealth model, AI-driven personalization and global expansion plans to outpace industry growth.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Published: August 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options
Read More
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: August 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).
Read More
Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies?
Published: August 11, 2025 by: Fast Company
Sentiment: Neutral
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profile telehealth company continues to sell compounded versions of Wegovy at lower prices, testing the limits of federal restrictions on such copies and contributing to weaker sales growth for Novo.
Read More
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Lost Money on Hims & Hers Health, Inc.(HIMS)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. (NYSE: HIMS)
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) between April 29, 2025 and June 22, 2025, inclusive. Should You Join This Class Action Lawsuit?
Read More
HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - HIMS
Published: August 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW ORLEANS , Aug. 8, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS), if they purchased the Company's securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"). These actions are pending in the United States District Court for the Northern District of California.
Read More
HIMS FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important August 25 Deadline in Securities Class Action – HIMS
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.
Read More
DEADLINE ALERT for HIMS, IRBT, CNC, BHVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
Published: August 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
BENSALEM, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Read More
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Published: August 08, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ("Hims" …
Read More
Hims & Hers Redefines Virtual Care With Integrated Tech Platforms
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.
Read More
Hims & Hers: Still Growing After Breakup With Novo Nordisk
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers is positioned as a leading telehealth platform targeting millennial and Gen Z consumers with affordable, accessible healthcare solutions. The company's strong revenue growth, expanding product offerings, and direct-to-consumer model support my positive outlook on the stock. HIMS's focus on recurring subscription revenue and high customer retention rates enhances long-term financial stability and growth potential.
Read More
Hims & Hers: GLP-1 Strategy Is On Dubious Grounds
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Negative
Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. The results reflect GLP-1 concerns. Hims & Hers' GLP-1 strategy is now on dubious grounds after Novo Nordisk ended the companies' partnership. The overall growth story continues regardless. Hims & Hers is launching new products and markets, while U.S. momentum has remained good in most other categories.
Read More
Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Aug. 6, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE: HIMS) have opportunity to lead the securities fraud class action lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Published: August 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Wait Out The GLP-1 Storm - Buy The Hims And Hers Post-Earnings Dip
Published: August 05, 2025 by: Seeking Alpha
Sentiment: Positive
Hims and Hers faced a short-term revenue dip due to regulatory changes and GLP-1 customer offboarding, but core growth remains strong. Subscriber numbers surged 31% quarter-over-quarter, and product diversification continues to drive long-term revenue expansion. Regulatory-driven shipment cadence changes should normalize by late 2025, supporting a rebound in average revenue per customer and total revenue.
Read More
HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and subscriber growth.
Read More
Weighing HIMS GLP-1 Trends, NVO Partnership & Other Businesses
Published: August 05, 2025 by: Schwab Network
Sentiment: Neutral
Michael Cherny sees opportunity for Hims & Hers (HIMS), as long as it can overcome headwinds facing its non-weight loss businesses. He argues the stock hasn't traded on fundamentals and weighs heavily on its GLP-1 drugs sales.
Read More
Deadline Alert: Hims & Hers Health, Inc. (HIMS) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).
Read More
Hims & Hers drops on revenue miss
Published: August 05, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Brandon Gomez joins 'Squawk on the Street' to discuss the latest earnings from Hims & Hers.
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - HIMS
Published: August 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Read More
What's Next For HIMS Stock?
Published: August 05, 2025 by: Forbes
Sentiment: Negative
Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong growth but did not meet revenue forecasts. The company disclosed revenue of $544.8 million, which reflects a strong 73% increase compared to the previous year, although it did not reach the $552 million consensus estimate.
Read More
Hims & Hers shares fall on mixed Q2 report, light revenue forecast
Published: August 05, 2025 by: Proactive Investors
Sentiment: Negative
Hims & Hers (NYSE:HIMS) shares fell 12% before US markets opened on Tuesday as the company posted mixed results for the second quarter and issued cautious guidance. The company reported revenue of $544.8 million, up 73% year-over-year, but short of Wall Street estimates of $552 million.
Read More
Wall Street sets HIMS' stock price for the next 12 months
Published: August 05, 2025 by: Finbold
Sentiment: Negative
As telehealth company Hims & Hers Health (NYSE: HIMS) navigates a turbulent short-term period following a disappointing Q2 2025 earnings report, some on Wall Street are projecting extended losses for the stock.
Read More
Hims & Hers Health, Inc. (HIMS) - Lawmakers Urge Crackdown On Illegal Weight Loss Drugs, Novo's Termination of Collaboration With HIMS Triggers Securities Class Actions -- Hagens Berman
Published: August 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- This latest development follows an announcement by Novo Nordisk on June 23, 2025, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it terminated its collaboration with Hims & Hers due to concerns about its sales and “deceptive” marketing of Wegovy®. Novo Nordisk's announcement triggered securities class action lawsuits against Hims & Hers Health, Inc. and certain of the company's executives, seeking to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025.
Read More
Hims & Hers Health, Inc. (HIMS) – Lawmakers Urge Crackdown On Illegal Weight Loss Drugs, Novo's Termination of Collaboration With HIMS Triggers Securities Class Actions – Hagens Berman
Published: August 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- On July 25, 2025, investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares significantly fall during intraday trading on reports that U.S. lawmakers urged the FDA to act against copycat versions of weight loss drugs, citing safety concerns.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Andrew Dudum
- Employees 1637